31results about How to "Improve disposal" patented technology

The invention aims to provide a method for preparing a docetaxel long-circulating liposome. The method comprises the following steps of: dissolving docetaxel and carrier materials such as phospholipid, cholesterol and the like together in an organic solvent; forming a film through rotary evaporation in a 40 to 70 DEG C water bath; adding buffer solution which contains a surfactant and performing refrigeration at the temperature of below 4 DEG C for 10 to 60 minutes to fully hydrate the film; and then mixing or stirring to obtain the docetaxel liposome. The liposome of 70 to 500nm is prepared from the docetaxel and can be prepared into docetaxel long-circulating liposome frozen powder for injection by lyophilization.

The subject invention provides materials and methods for reducing deleterious atmospheric gases, such as greenhouse gases. In specific embodiments, the reduction in deleterious atmospheric gases is achieved via enhanced vegetative carbon utilization and storage, as well as increased carbon sequestration in soil. In some embodiments, the subject invention can be used for reducing the number of carbon credits used by an operator involved in, e.g., agriculture, livestock production, waste management or other industries. In certain embodiments, the subject invention provides customizable microbe-based products, as well as methods of using these microbe-based products for reduction of greenhouse gases and/or enhanced sequestration of carbon.

The invention discloses a hydroxyl camptothecin flexible liposome and a preparation method thereof. The method comprises the following steps of: dissolving hydroxyl camptothecin and carrier materials, such as phospholipid, cholesterol and the like, in an organic solvent; forming the mixture into a membrane in water bath through rotary evaporation; and adding buffer solution which contains chitosan into the membrane to form the hydroxyl camptothecin flexible liposome. The hydroxyl camptothecin flexible liposome is relatively lower in toxicity, relatively longer in residence time in a body, high in stability in a solution phase and smalllow in particle size, and the particle size of the liposome is not obviously changed after the liposome is lyophilized.

The invention concerns a peptide based on biologically active CCK-8. The peptide has improved characteristics for the treatment of at least one of obesity and type 2 diabetes and has the structure:

(Z)-Asp¹-Aaa²(X)-Aaa³Gly⁴Trp⁵Aaa⁶Asp⁷(Y)Aaa⁸K,

wherein the amino acids may be either D or L amino acids; the bond between amino acid residues is either a peptide bond or a non-peptide isostere bond; Aaa² is selected from the group comprising Tyr and Phe; when Aaa² is Tyr, X is selected from the group comprising SO₃H⁻, PO₃H₂⁻ and a polymer moiety of the general formula —O—(CH₂—O—CH₂)_n—H, in which n is an integer between 1 and about 22, wherein the X is covalently bound to the para phenyl oxygen of Tyr, and, when Aaa² is Phe, X is CH₂SO₃Na, wherein the X is covalently bound to the para phenyl position of Phe; Aaa³ is selected from the group comprising Met, norleucine, 2-aminohexanoic acid and Thr; Aaa⁶ is selected from the group comprising Met, norleucine, 2-aminohexanoic acid and Phe; Aaa⁸ is selected from the group comprising Phe and Met; Y is covalently bound to the nitrogen of Aaa⁸ and is selected from the group consisting of H and CH₃; K is selected from the group consisting of the hydroxyl group of Phe⁸, an amide covalently bound to Phe⁸, an ester covalently bound to Phe⁸, a salt of the hydroxyl group of Phe⁸, a salt of an amide covalently bound to Phe⁸, a salt of an ester covalently bound to Phe⁸ and a polymer moiety of the general formula —O—(CH₂—O—CH₂)_n—H, in which n is an integer between 1 and about 22; and Z comprises at least one amino acid modification, wherein said at least one modification comprises an N-terminal extension, or an N-terminal modification, but excludes Asp¹-glucitol CCK-8 where Aaa² is Tyr and X is SO₃H⁻.

The peptides, and Asp¹-glucitol CCK-8, are useful to at least one of inhibit food intake, induce satiety, stimulate insulin secretion, moderate blood glucose excursions, enhance glucose disposal and exhibit enhanced stability in plasma compared to native CCK-8

New gene therapy constructions and compositions are the subject of present invention. The gene therapy compositions consist in adeno-associated vectors which jointly express insulin (Ins) and glucokinase (Gck) genes. The new gene therapy constructions are useful for treatment of diabetes either in dogs or human beings.

Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.